This means that it could be used in combination with GLP-1s to possibly enhance weight loss or simply offer an alternative to these drugs. Second, and one reason why someone might choose a CB1 drug ...

CB1 receptor antagonists, such as the aforementioned rimonabant and taranabant, were found to regulate food intake and adipose tissue metabolism, resulting in weight loss and favorable blood lipid ...

This clinical trial is a randomized, double-blind study designed to enroll 120 patients across four treatment groups. The ...

Skye Bioscience (SKYE) announced preliminary data from a diet-induced obesity model in mice. Skye’s CB1-inhibiting antibody, nimacimab, ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 ...

The third quarter marked an important transition for Skye as a metabolic-focused company with the launch of our Phase 2 obesity clinical trial for nimacimab. We believe our truly ...

Q3 2024 Earnings Call Transcript November 7, 2024 Skye Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.25. Operator: Ladies and gentlemen, thank you for ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean mice Dose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to 38% weight loss in DIO mice ... its highly peripherally ...